characterizing sars-cov-2-specific immunity in individuals who have recovered from covid-19

Conditions: SARS-CoV-2; COVID-19

Summary: the purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (sars-cov-2). some people know this virus by the name "coronavirus." it can cause the disease called covid-19. the information gained from the study will be used to help develop better tests for sars-cov-2 infection and covid-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural sars-cov-2 infection and immunization with a sars-cov-2 vaccine.

this study aims to characterize the sars-cov-2-specific immunity in convalescent individuals. the observational cohort study will include 3 groups, as described in the table below. participants will complete a minimum of one visit (1-8 weeks post resolution of covid-19 or 2-10 weeks post most recent positive sars-cov-2 test, if asymptomatic) and optional visits approximately 2 months, 4 months, and 1 year later. participants diagnosed with sars-cov-2 infection at an optional follow-up visit may be contacted more frequently. additional follow up visit(s) may be added over time in response to evolving information regarding sars-cov-2 infection and covid-19. study visits may include physical examinations, medical history, questionnaires, pregnancy tests (for participants assigned female at birth), blood draws, optional nasal samples, and optional hiv testing.

Eligibility criteria:
inclusion criteria: * age 18 or older. * reports having had a positive test for sars-cov-2. * reports resolution of covid-19 within 1-8 weeks of enrollment or, if asymptomatic infection, reports positive sars-cov-2 test within 2-10 weeks of enrollment. not excluded: individuals with symptoms consistent with residual sequelae of resolved covid-19, in the clinical judgement of the investigator. * access to a participating hvtn or hptn crs and willingness to be followed for the planned duration of the study. * ability and willingness to provide informed consent. * assessment of understanding: volunteer demonstrates understanding of this study. * volunteers who were assigned female sex at birth: negative urine or serum beta human chorionic gonadotropin (β-hcg) pregnancy test within 4 days of enrollment visit (ie, prior to enrollment blood draw or nasal collections). persons who are not of reproductive potential due to having undergone hysterectomy or bilateral oophorectomy (verified by medical records) or having reached menopause (no menses for ≥ 1 year ), are not required to undergo pregnancy testing. exclusion criteria: * reports current covid-19. * pregnant. * receipt of sars-cov-2 specific antibodies (eg, convalescent plasma or sera, monoclonal antibodies, hyperimmune globulin). not excluded: antibody therapy without sars-cov-2 specificity (eg, il-6 pathway inhibitors for covid-19). * sars-cov-2 vaccine(s) received in a prior vaccine trial. * any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or a volunteer's ability to give informed consent.